Altimmune (ALT) Expected to Announce Quarterly Earnings on Thursday

Altimmune (NASDAQ:ALT) is expected to be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Altimmune to post earnings of ($0.25) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Altimmune Trading Down 0.9%

Shares of ALT stock opened at $4.46 on Thursday. Altimmune has a 12-month low of $2.90 and a 12-month high of $7.73. The company has a market capitalization of $503.22 million, a PE ratio of -4.17 and a beta of 0.09. The firm has a 50 day moving average price of $4.56 and a two-hundred day moving average price of $4.23. The company has a quick ratio of 17.18, a current ratio of 17.18 and a debt-to-equity ratio of 0.08.

Insider Buying and Selling

In related news, Director Jerome Benedict Durso purchased 12,500 shares of Altimmune stock in a transaction on Monday, December 22nd. The stock was acquired at an average cost of $4.13 per share, for a total transaction of $51,625.00. Following the completion of the acquisition, the director owned 12,500 shares of the company’s stock, valued at $51,625. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John Gill acquired 12,500 shares of the company’s stock in a transaction dated Tuesday, December 23rd. The shares were bought at an average price of $4.10 per share, for a total transaction of $51,250.00. Following the acquisition, the director directly owned 12,500 shares of the company’s stock, valued at approximately $51,250. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders acquired 30,527 shares of company stock valued at $125,278. 4.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Altimmune

Several institutional investors have recently bought and sold shares of ALT. Vines Capital Management LLC bought a new stake in Altimmune during the fourth quarter worth $65,000. Virtus Investment Advisers LLC raised its holdings in shares of Altimmune by 217.2% in the 4th quarter. Virtus Investment Advisers LLC now owns 50,482 shares of the company’s stock worth $182,000 after purchasing an additional 34,568 shares during the period. Quadrature Capital Ltd bought a new position in Altimmune during the fourth quarter valued at $36,000. Man Group plc purchased a new position in shares of Altimmune during the 4th quarter valued at $68,000. Finally, Engineers Gate Manager LP raised its stake in Altimmune by 112.6% in the 4th quarter. Engineers Gate Manager LP now owns 87,264 shares of the company’s stock valued at $315,000 after acquiring an additional 46,221 shares during the period. Institutional investors own 78.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on ALT shares. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. Citizens Jmp reduced their price objective on Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a research report on Friday, November 7th. Barclays initiated coverage on Altimmune in a report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 target price for the company. Finally, Citigroup reissued a “market outperform” rating on shares of Altimmune in a research note on Wednesday, November 12th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Altimmune has an average rating of “Hold” and an average price target of $17.60.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.